https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Patient and health care professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: a cross sectional survey. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54477 Tue 27 Feb 2024 14:56:37 AEDT ]]> Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46000 C and ABCB1_c.3435C > T were included in the final model, whereby CLSN38 reduced from 76.8 to 55.1%. Conclusion: The identified UGT1A3_c.31 T > C and ABCB1_c.3435C > T variants, from wild type to homozygous, were included in the final model for SN38 clearance.]]> Tue 08 Nov 2022 16:32:22 AEDT ]]> Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32260 Thu 01 Jun 2023 10:46:47 AEST ]]>